CA Patent

CA2896055C — Compositions and methods for transdermal delivery of amphetamine and clonidine

Assigned to Noven Pharmaceuticals Inc · Expires 2021-02-16 · 5y expired

What this patent protects

Described are compositions and methods for combination therapy using a stimulant therapeutically active agent (such as amphetamine) and a non-stimulant therapeutically active agent (such as clonidine), such as for the treatment of Attention Deficit Disorder (ADD) and/or Attention…

USPTO Abstract

Described are compositions and methods for combination therapy using a stimulant therapeutically active agent (such as amphetamine) and a non-stimulant therapeutically active agent (such as clonidine), such as for the treatment of Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Methods of making and using such systems also are described.

Drugs covered by this patent

Patent Metadata

Patent number
CA2896055C
Jurisdiction
CA
Classification
—
Expires
2021-02-16
Drug substance claim
No
Drug product claim
No
Assignee
Noven Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.